Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor‐Related Myocarditis: A Real World Observational Study
Clinical Cardiology · 2026-04 · 49 (4)
DOI: 10.1002/clc.70312 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, online erschienen am 20.04.2026. Verfasst von Mei Zhan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Chia-Tai Tianqing Pharmaceutical Company.
Abstract (Originalsprache)
Background
Rare occurrence, immune checkpoint inhibitors (ICI)‐related myocarditis are poorly documented in the literature. Research Design and Methods We conducted a retrospective review of patients who had ICI until June 2023. Patient follow‐up was extended until death or on May 2024. The primary outcome was the incidence of suspected ICI‐related myocarditis. Logistic regression was used to investigate the associations between clinical characteristics and suspected ICI‐related myocarditis.
Results
Among the included 8199 patients, 1638 (19.98%) patients developed suspected ICI‐related myocarditis. Logistic regression revealed that thymomas and thymic carcinomas (OR 2.242; [95% CI, 1.132–4.440], p = 0.021), lung cancer (OR 1.259; [95% CI, 1.119–1.416], p < 0.001), older patients (OR 1.021; [95% CI, 1.016–1.026], p < 0.001), male (OR 1.213; [95% CI, 1.061–1.388], p = 0.005), block two or more immune checkpoints (OR = 1.391 [95% CI 1.058–1.828], p = 0.018), combined with hypertension (OR = 1.326 [95% CI 1.162–1.513], p < 0.001), or hyperlipidemia (OR = 1.656 [95% CI 1.302–2.107], p < 0.001) were associated with higher risk of suspected ICI‐related myocarditis.
Conclusions
This large, real‐world cohort demonstrates that the incidence of suspected ICI‐related myocarditis may be underestimated in previous literature. Routine cardiac surveillance is needed in high‐risk patients receiving ICI therapy. Trial Registration Registered at https://www.chictr.org.cn (identifier: ChiCTR2300075974).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Engineering Research Center of Medical Information Technology, Ministry of Education, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Mei Zhan, Litao Huang, Jinhan He
Förderung
- Nanjing Chia-Tai Tianqing Pharmaceutical Company
Zitieren
APA
Zhan, M., Long, Q., Liu, R., Huang, L., Wu, B., Xu, T., & He, J. (2026). Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor‐Related Myocarditis: A Real World Observational Study. Clinical Cardiology, 49(4). https://doi.org/10.1002/clc.70312
Vancouver
Zhan M, Long Q, Liu R, Huang L, Wu B, Xu T, et al. Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor‐Related Myocarditis: A Real World Observational Study. Clinical Cardiology. 2026;49(4). doi:10.1002/clc.70312
BibTeX
@article{Zhan2026,
author = {Zhan, Mei and Long, Qinran and Liu, Ran and Huang, Litao and Wu, Bin and Xu, Ting and He, Jinhan},
title = {Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor‐Related Myocarditis: A Real World Observational Study},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {4},
doi = {10.1002/clc.70312}
}
EUVIMED